ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
August 13 2024 - 4:05PM
Business Wire
ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a
pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today
announced that it will host a conference call and webcast beginning
at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly
results, provide an update on recent corporate developments and
answer questions. This call was previously scheduled for August 14,
2024.
The Company will file its quarterly report on form 10-Q with the
SEC as regularly scheduled in the coming days. A press release
summarizing its financial and operating results for the second
quarter ending on June 30, 2024, will be issued on the day of the
call.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will receive a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the start of the call. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call can also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until August 29, 2024 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 5567407. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology that
characterizes tissue similar to an MRI, but at 1/40th the cost and
at the point of patient care. TAEUS® is designed to work in concert
with the more than 700,000 ultrasound systems in use globally
today. TAEUS® is initially focused on the non-invasive assessment
of fatty tissue in the liver. Steatotic liver disease (SLD,
formerly known as NAFLD-NASH) is a chronic liver disease spectrum
that affects over two billion people globally, and for which there
are no practical diagnostic tools. Beyond the liver, ENDRA is
exploring several other clinical applications of TAEUS®, including
non-invasive visualization of tissue temperature during
energy-based surgical procedures. For more information, please
visit www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813212894/en/
Company: Richard Jacroux Chief Financial Officer
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2023 to Aug 2024